Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

Angiogenesis inhibitors can be divided in 2 main groups according to their mechanism of action [3]: those that act directly on microvascular endothelial cells recruited by the tumor, such as ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

1Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, P ...

Introduction: DNA methylation inhibitors have been approved for the prevention of Acute Myeloid Leukemia (AML), and their safety profile is not fully characterized. This study was aimed at evaluating ...

In this report, we will discuss some of the AACR data relating to angiogenesis in light of previous results from clinical trials, attempting to outline what has been achieved so far and what are ...

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...

CAR T cells show contrasting approaches to killing cancer, with one sprinting for fast action and the other collaborating for endurance. Scientists are now focusing on adapting these cells to outsmart ...

These compounds are designed to specifically target and inhibit KRAS alleles, providing both therapeutic and prophylactic potential in mammals, particularly for the treatment of KRAS-driven cancers.

The Park Nicollet Institute is actively enrolling women with recurrent ovarian cancer for participation in a new clinical research study, called TRINOVA-2. Although there have been many ...